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Abstract Ephrins and Eph receptors have been implicated to
play important roles in axon guidance. A variable spacer region
exists that differs significantly among distinct ephrins. An
ephrin-A5 isoform has previously been isolated which lacks 27
amino acids within the spacer region. The expression and
biological activities of this isoform, as well as the existence of
isoforms for other ephrins that show variation within the spacer
region, remain unknown. We report here a novel alternatively
spliced isoform of ephrin-A3 which lacks the corresponding
variable region. When compared to the longer isoforms, the
shorter isoforms of both ephrin-A3 and ephrin-A5 remained less
prominent in the brain during development, though their
expression increased at postnatal stages. In addition, they could
inhibit neurite outgrowth of dorsal root ganglia (DRG) neurons,
suggesting that the corresponding variable regions were not
essential for their axon guidance activities.
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1. Introduction
Eph receptor interacting proteins (Ephrins) have been dem-
onstrated to act as positional cues in axon guidance and em-
bryonic segmentation [1,2]. They are membrane-bound pro-
teins and the membrane anchorage is essential for their
activities [3]. Ephrins are classi¢ed into two classes based on
their mode of attachment: those that anchor to the membrane
by glycosylphosphatidylinositol (GPI) linkage are classi¢ed as
ephrin-A, while ephrin-B ligands contain a transmembrane
domain. Both classes of ephrins mediate their activities
through interactions with the Eph receptor tyrosine kinases.
Binding studies reveal that ephrin-A ligands interact selec-
tively with EphA receptors while ephrin-B ligands bind to
the EphB receptors and there is little cross-reactivity between
members of the di¡erent classes [4]. However, a high degree of
promiscuous binding is exhibited among di¡erent members of
the same class, though there are wide variations in the binding
a⁄nities [4]. The binding promiscuity suggests certain degrees
of functional redundancy among di¡erent ephrins and their
receptors. The repulsive guidance activity of ephrins was ¢rst
demonstrated in the retinotectal system [5^7]. Subsequently,
ephrins were found to be involved in guidance of other neu-
rons in both CNS and PNS [8^13].
There are eight ephrins isolated thus far. They share 30^
70% amino acid identity in their core regions, where four
conserved cysteine residues are present [2]. Moreover, there
is a conserved gene structure for di¡erent ephrins, i.e. the
gene is encoded by four or ¢ve exons with conserved intron/
exon structure [14]. However, a spacer region in the carboxyl
terminal half di¡ers signi¢cantly in both the length and amino
acid composition among di¡erent ephrins [15]. Isoforms for
two of the ephrins had previously been identi¢ed. An alter-
natively spliced isoform of ephrin-B2 was reported in which a
conserved region of 31 amino acid residues including the
fourth invariable cysteine was deleted [16]. On the other
hand, an ephrin-A5 isoform which lacked 27 amino acid res-
idues within the spacer region had been identi¢ed [17]. How-
ever, little was known about the expression and function of
these isoforms. In addition, the existence of isoforms for other
ephrins had not been reported.
Our studies aim to characterize the short isoform of ephrin-
A5 and to look for isoforms for other ephrins. Using RT-
PCR, we cloned a novel isoform of ephrin-A3, which lacked
26 amino acids within the spacer region. Interestingly, the
deletion that gave rise to the shorter isoforms of ephrin-A3
and ephrin-A5 occurred at the corresponding region. The rel-
ative expression of the short isoforms of both ephrins in-
creased in the brain during later stages of development. Fur-
thermore, both isoforms inhibited neurite outgrowth of dorsal
root ganglia (DRG), suggesting that the deleted variable re-
gions are not required for their repulsive guidance activities.
2. Materials and methods
2.1. Cloning of rat ephrin-A3 and ephrin-A5, and the construction of
Fc-tagged fusion proteins
The short isoform of ephrin-A3 was ¢rst identi¢ed by RT-PCR
from adult rat brain RNA using a pair of primers £anking the posi-
tion where deletion of ephrin-A5 occurred (5P-GTACGTGCTGTA-
CATGG and 5P-CTAGGAGGCCAAGAACGTC). The full-length
rat ephrin-A3 was subsequently ampli¢ed from adult brain cDNA
using Vent polymerase by primers derived from human ephrin-A3
that contained the starting methionine and the stop codon: 5P-
GGGGATGGCGGCGGCTC and 5P-CTAGGAGGCCAAGAAC-
GTC. On the other hand, the short isoform of ephrin-A3 was made
by deleting the variable region from the full-length construct, using
Vent polymerase with internal primers corresponding to the deleted
region, as previously described [18]. The full-length ephrin-A5 and its
shorter isoform were ampli¢ed from rat astrocyte cDNA by Vent
polymerase, using the primers 5P-GCTAGGCGTGATGTTGC and
5P-GCTATAATGTCAAAAGCATCGCCAG. All the full-length con-
structs were subcloned into the expression vector pCDNA3neo. Fu-
sion proteins of ephrin-A3 and ephrin-A5, in which their C-termini
were tagged with the Fc-epitope, were made by amplifying the corre-
sponding fragments up to the region near their hydrophobic ends
using Vent polymerase. The fragments were subsequently fused with
the Fc portion of human IgG in the expression vector pMT21 as
previously described [18]. The identities of all the full-length con-
structs were veri¢ed by DNA sequencing.
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2.2. Northern blotting and RT-PCR analysis of ephrin expression
Total RNA was collected from di¡erent tissues, and 15 mg of each
was electrophoresed on a 1% agarose-formaldehyde gel and trans-
ferred onto nylon membrane. For RT-PCR, total RNA was reverse
transcribed using Superscript RT (Gibco, NY, USA) and PCR was
performed by primers £anking the variable regions of the two ephrins
(for ephrin-A3, they were the ones used in the identi¢cation of the
short isoform mentioned above; for ephrin-A5, the primers were 5P-
GGACCGCTGAAGTTCTCG and 5P-GCTATAATGTCAAAAG-
CATCGCCAG). Twenty-¢ve cycles of ampli¢cation were employed
(except for the expression of ephrin-A3 and ephrin-A5 in muscle and
liver, in which 30 cycles were performed). The PCR products were
analyzed by 1.2% agarose gel and Southern blotting. Both the South-
ern and Northern blots were hybridized with probes that correspond
to full-length rat ephrin-A3 and ephrin-A5.
2.3. Binding assay of Fc-tagged ephrins
In our study, the interactions between the receptor EphA3 and the
isoforms of ephrin-A3 and ephrin-A5 were determined. Full-length
EphA3 was ampli¢ed from E16 rat brain RNA by RT-PCR using
Vent polymerase and was subsequently subcloned into pCDNA3neo.
To construct stable 293 ¢broblast line expressing EphA3, the cells
were transfected by lipofectamine using the protocol recommended
by the supplier (Gibco, NY, USA), followed by selection in medium
containing 600 Wg/ml G418. Stable clones were isolated and their
expression of EphA3 receptor was screened by staining with Cos
cell supernatant containing Fc-tagged ephrin-A5, performed as previ-
ously described [4]. Fc-tagged ephrins were produced by transfecting
the DNA constructs into Cos-5 cells using DEAE-dextran as previ-
ously described [18]. Three days after transfection, the conditioned
medium was collected. The amount of di¡erent Fc-tagged proteins
were quanti¢ed by ELISA using HRP-anti-human Fc antibody
(Amersham, UK).
The binding assay was performed as previously described [4].
Brie£y, EphA3-expressing 293 cells (7U106) were plated 2 days before
assay. They were then incubated with conditioned medium that con-
tained equalized amount of Fc-tagged ephrin-A3 or ephrin-A5 iso-
forms. An unrelated protein, Fc-tagged neurotrophin-7, acted as the
negative control in the binding assay. After washing, the cells were
incubated with anti-human antibody conjugated with alkaline phos-
phatase (Promega, WI, USA). The cells were then washed with the
phosphatase inhibitor levamisole and the cell lysate was collected. The
enzyme activity was assayed by using PNPP as the substrate and the
absorbance at 405 nm was measured. Since 293 ¢broblasts expressed a
low level of endogenous EphA receptors, as revealed by staining with
Fc-tagged ephrin-A5, the absorbance values obtained by mock-trans-
fected 293 were subtracted for each Fc-tagged protein in order to
assess their interactions with EphA3 receptors.
Fig. 1. Sequence of rat ephrin-A3 and its alignment with ephrin-A5. A: Nucleotide and the deduced amino acid sequences of rat ephrin-A3.
The full-length sequence was ampli¢ed by PCR using primers derived from human ephrin-A3 (underlined). B: Alignment of ephrin-A3 with rat
ephrin-A5. The four conserved cysteine residues (dark) and their corresponding regions deleted in the shorter isoforms (shaded) were indicated.
Arrowheads represented the positions where the Fc region of human IgG was fused to the ligands for binding assay (see below). C: Alternative
splicing of exon 4 resulted in the substitution of 188Glu by Lys.
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2.4. Co-culture of DRG explants with stable 293 cells that expressed
di¡erent ephrin-A3 and ephrin-A5 isoforms
Stable lines of 293 ¢broblasts were made by transfecting the cells
with each isoform of ephrin-A3 and ephrin-A5 encoded in pCNA3neo
(or the vector alone for the mock-transfected stable clones). The pos-
itive clones were selected by staining with Fc-tagged EphA5 at a
concentration of 1 mg/ml. The expression of speci¢c ephrin isoform
by each individual clone was con¢rmed by RT-PCR using the primers
that £anked the variable regions mentioned above (data not shown).
For co-culture with chicken DRG explants, stable 293 (1U106) were
plated 1 day prior to co-culture. DRG from embryonic day 8 chickens
were placed onto the ¢broblasts and neurite outgrowth was induced
by nerve growth factor at 1 ng/ml. After 2 days incubation, the co-
culture was ¢xed and immunostained with anti-neuro¢lament 160-
kDa antibody (clone NN18, Sigma, MO, USA) diluted at 1:200.
Two di¡erent clones of stable 293 for each ephrin isoform and the
mock-transfected control were analyzed in the co-culture experiments.
3. Results and discussion
3.1. Cloning of rat ephrin-A3 and its isoform
The cDNA and protein sequences of rat ephrin-A3 had not
been reported. In this study, the full-length ephrin-A3 was
isolated from adult rat brain cDNA (Fig. 1A). While it shared
97% amino acid identity to human ephrin-A3 [3,15], it was
100% identical to the partial sequence of the mouse homolog
[14]. A novel isoform of ephrin-A3 was identi¢ed from adult
brain by RT-PCR. It lacked the highly variable 26 amino acid
residues within the spacer region and the 188Glu was substi-
tuted by a Lys residue (Fig. 1B, C). The deleted region cor-
responded precisely to the sequence encoded by exon 4 [14],
indicating that the isoform was likely to be derived from al-
ternative splicing. Interestingly, the deleted sequence corre-
sponded to the region that was spliced to generate the eph-
rin-A5 isoform reported previously [17]. However, using the
same approach, we were not able to isolate isoforms for other
ephrins that contained insertion or deletion at the correspond-
ing position. The longer isoforms of both ephrins that con-
tained the variable regions were designated the K-isoforms,
while their shorter isoforms were named as the L-isoforms.
3.2. Expression of the K- and L-isoforms
The expression pro¢les of individual isoforms of both eph-
rins were examined by RT-PCR. Both isoforms of ephrin-A3
and ephrin-A5 were expressed in the brain and their expres-
sion was developmentally regulated (Fig. 2A). Interestingly,
while the L-isoforms remained less prominent throughout de-
velopment, their relative expression increased considerably at
postnatal stages of the brain. Moreover, both isoforms were
found in di¡erent brain regions in adults, though the relative
expression of the K- and L-isoforms appeared to be similar in
distinct brain areas (Fig. 2B). Thus, the L-isoforms of ephrin-
A3 and ephrin-A5, despite their lower abundance compared
with the K-isoforms, are expressed early in development when
precise axonal connections are being made, suggesting their
potential involvement in axon guidance. In addition, the in-
creased expression of the L-isoforms at late embryonic and
early postnatal stages raised the possibility that the L-isoforms
might perform speci¢c functions in the brain.
The relative expression of ephrin isoforms outside the nerv-
ous system was also examined. Both isoforms were expressed
in muscle and liver and the L-isoforms were less abundant
(Fig. 2C). It was noteworthy that the expression of both eph-
rin-A3 and ephrin-A5 was drastically down-regulated in
muscle during development. Ephrins had been implicated to
Fig. 2. Expression of ephrin isoforms as revealed by RT-PCR.
A: Expression of isoforms at di¡erent developmental stages of the
brain. The expression of the shorter L-isoforms of both ephrins in-
creased at later developmental stages, though they remained less
prominent compared with their respective long isoforms (K-iso-
forms). B: Both isoforms were expressed in di¡erent brain areas in
adult rat. C: Both isoforms were expressed in muscle and liver, but
the L-isoforms were less prominent. Down-regulation of both li-
gands was observed during muscle development. E14 to E21, from
embryonic day 14 to 21. P1 to P60, from postnatal day 1 to 60.
Con represented the negative control in which no RNA was added
in the RT reaction (same result was obtained for the negative con-
trol without reverse transcriptase; data not shown).
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confer rostral/caudal identity of skeletal muscles [13], yet the
developmental expression pro¢le of any ephrin in muscle re-
mained unknown. We therefore attempted to examine the
developmental regulation of ephrin-A3 and ephrin-A5 expres-
sion in muscle by Northern blot analysis (Fig. 3). Multiple
transcripts for both ephrins were detected, in contrast to the
single transcript observed for the other ligands [19^22]. Con-
sistent with the RT-PCR analysis, down-regulation of ephrin-
A3 and ephrin-A5 expression was observed. Indeed, both li-
gands were abundant in embryonic skeletal muscle, which was
not revealed by previous reports that examined the spatial
expression of ephrins in adult tissues. The high expression
of ephrins in embryonic muscle supports their proposed roles
in guiding sensory and motor neurons [13,23].
3.3. Binding of ephrin isoforms to EphA3
Binding assays were performed in order to test whether
splicing of the corresponding variable regions from ephrin-
A3 and ephrin-A5 would disrupt binding to their cognate
Eph receptors. Each ephrin isoform was tagged with the Fc
region of human IgG, and its binding to ¢broblasts that over-
expressed EphA3 was examined. The binding of EphA3 to the
Fig. 3. Northern blot analysis of ephrin-A3 and ephrin-A5 in
muscle during development. Multiple transcripts were observed for
both ligands (arrowheads). Both ephrin-A3 and ephrin-A5 were rel-
atively abundant at embryonic stages but the expression decreased
along muscle development. The positions of the ribosomal RNA
were indicated (18S and 28S).
Fig. 4. Binding assay of ephrin isoforms to EphA3. Fc-tagged eph-
rin was added to stable 293 ¢broblasts that over-expressed EphA3
and the absorbance represented the amount of ephrin-Fc fusion pro-
teins bound to the EphA3-expressing cells. The negative value for
NT-7, an unrelated Fc-fusion protein which acted as the negative
control was obtained as a result of subtraction from the absorbance
value of mock-transfected 293 cells. The di¡erences in absorbance
between the two ephrins and their isoforms were not signi¢cant
(Ps 0.005). The error bars represent S.D., n = 5.
Fig. 5. Inhibition of neurite extension by ephrin-A3 and ephrin-A5. A: Stable 293 ¢broblasts that expressed either the vector alone (mock) or
individual isoform of ephrin-A5 were co-cultured with DRG explants. Both the K- and L-isoforms of ephrin-A5 could inhibit neurite extension
from DRG. B: Similar approach demonstrated that both isoforms of ephrin-A3 inhibited neurite extension by DRG.
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K- and L-isoform of both ephrins was similar, suggesting that
their respective variable regions deleted in the L-isoforms were
not essential in binding to the receptor (Fig. 4). In addition,
EphA3 could be phosphorylated upon stimulation with the L-
isoform of both ephrins (data not shown). These observations
agree with the proposed structure-function model in which the
more conserved N-terminal half of the molecule that con-
tained the four invariant cysteine residues is involved in re-
ceptor binding, while the variable spacer region is not [15].
3.4. Repulsive guidance activities of ephrin isoforms
Although the variable regions were not involved in receptor
binding, they might be important in mediating the repulsive
guidance activities of ephrins. Ephrin-A5, when expressed in
¢broblasts, had been demonstrated to inhibit neurite out-
growth of DRG explants [13], which was reminiscent of the
repulsive guidance activities. In our study, DRG explants
were placed onto a con£uent layer of stable 293 ¢broblasts
that expressed the individual isoform of either ephrin and the
resulting neurite outgrowth was observed. Both the K- and L-
isoforms of ephrin-A5 inhibited neurite outgrowth of DRG,
and the extent of inhibition was similar (Fig. 5A).
Despite its prominent expression in the nervous system,
there was no evidence that ephrin-A3 can guide axon by re-
pulsion. When DRG were co-cultured with stable 293 ¢bro-
blasts that expressed ephrin-A3, the neurite extension was
inhibited (Fig. 5B). Therefore, our ¢nding raised the possibil-
ity that ephrin-A3 might also act as a repulsive guidance cue
for neurons. In addition, both the K- and L-isoforms could
inhibit neurite extension (Fig. 5B).
The presence of both the K- and L-isoforms in developing
brain and muscle, together with the ¢ndings that both iso-
forms are able to inhibit neurite outgrowth in vitro, suggested
that they may co-operate in the development of topographic
mapping. It is likely that both isoforms guide axons by repul-
sion. Although the two isoforms were indistinguishable in the
binding and neurite inhibition assays, they might exhibit dis-
tinct receptor speci¢cities. Alternatively, di¡erential signal
transduction pathways might be induced by the two isoforms.
It was reported that the extent of ephrin oligomerization
could in£uence the formation of signaling complexes and
the subsequent cellular responses [24]. It remained to be
seen whether the two isoforms might di¡erentially activate
the Eph receptors in a similar manner. The possibility of dis-
tinct receptor speci¢cities as well as signaling pathways would
represent a mechanism to increase the precision of topo-
graphic mapping.
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